VIDEO: Lowering cardiovascular risk factors necessary in psoriatic disease treatment
Click Here to Manage Email Alerts
WAILEA, Hawaii — Bolstered by Mendelian randomization studies linking coronary artery disease and psoriasis, researchers are exploring how to combat cardiovascular events in patients with psoriatic disease, according to a presenter here.
At the Maui Derm meeting, Joel M. Gelfand, MD, MSCE, the James J. Leyden Professor of Dermatology and Epidemiology at the University of Pennsylvania, delivered a lecture regarding different treatment options for psoriasis and how they compare in lowering cardiovascular risk factors.
The main points, which Gelfand summarizes in this Healio video exclusive, included studies on tumor necrosis factor inhibitors as compared with other pathway inhibitors and research on apremilast that found a reduction in visceral adiposity.
“What we really know we need to do is lower cardiovascular event rates in people with psoriatic disease by doing a better job of identifying traditional cardiovascular risk factors — like cholesterol, like diabetes and things of that nature — and treating them appropriately so they have a better cardiovascular profile in the future,” Gelfand said.